Relationship between Sex, Body Size, and Cardiac Resynchronization Therapy Benefit: A Patient Level Meta-Analysis of Randomized Controlled Trials

Daniel J Friedman*, Antonio Olivas-Martinez, Frederik Dalgaard, Marat Fudim, William T Abraham, John G F Cleland, Anne B Curtis, Michael R Gold, Valentina Kutyifa, Cecilia Linde, Anthony S Tang, Fatima Ali-Ahmed, Lurdes Y T Inoue, Gillian D Sanders, Sana M Al-Khatib

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

BACKGROUND: Women might benefit more than men from cardiac resynchronization therapy (CRT) and do so at shorter QRS durations.

OBJECTIVE: This meta-analysis was performed to determine whether sex-based differences in CRT effects are better accounted for by height, body surface area (BSA), or left ventricular end-diastolic dimension (LVEDD).

METHODS: We analyzed patient-level data from CRT trials (MIRACLE, MIRACLE ICD, MIRACLE ICD II, REVERSE, RAFT, COMPANION, and MADIT-CRT) using bayesian hierarchical Weibull regression models. Relationships between QRS duration and CRT effects were examined overall and in sex-stratified cohorts; additional analyses indexed QRS duration by height, BSA, or LVEDD. End points were heart failure hospitalization (HFH) or death and all-cause mortality.

RESULTS: Compared with men (n = 5628), women (n = 1439) were shorter (1.62 [interquartile range, 1.57-1.65] m vs 1.75 [1.70-1.80] m; P < .001), with smaller BSAs (1.76 [1.62-1.90] m 2 vs 2.02 [1.89-2.16] m 2; P < .001). In adjusted sex-stratified analyses, the reduction in HFH or death was greater for women (hazard ratio, 0.54; credible interval, 0.42-0.70) than for men (hazard ratio, 0.77; credible interval, 0.66-0.89; P interaction = .009); results were similar for all-cause mortality even after adjustment for height, BSA, and LVEDD. Sex-specific differences were observed only in nonischemic cardiomyopathy. The effect of CRT on HFH or death was observed at a shorter QRS duration for women (126 ms) than for men (145 ms). Indexing QRS duration by height, BSA, or LVEDD attenuated sex-specific QRS duration thresholds for the effects of CRT on HFH or death but not on mortality.

CONCLUSION: Although body size partially explains sex-specific QRS duration thresholds for CRT benefit, it is not associated with the magnitude of CRT benefit. Indexing QRS duration for body size might improve selection of patients for CRT, particularly with a "borderline" QRS duration.

OriginalsprogEngelsk
Sider (fra-til)845-854
Antal sider10
TidsskriftHeart Rhythm
Vol/bind21
Udgave nummer6
Tidlig onlinedato14 feb. 2024
DOI
StatusUdgivet - jun. 2024

Bibliografisk note

Copyright © 2024. Published by Elsevier Inc.

Fingeraftryk

Udforsk hvilke forskningsemner 'Relationship between Sex, Body Size, and Cardiac Resynchronization Therapy Benefit: A Patient Level Meta-Analysis of Randomized Controlled Trials' indeholder.

Citationsformater